Treatment of hormonally refractory cancer of the prostate with antineoplaston AS2-1.

Burzynski, S R; Kubove, E; Burzynski, B

Burzynski, S R; Kubove, E; Burzynski, B.

Affiliation

Burzynski SR; Burzynski Research Institute, Inc., Stafford, TX 77477.

Drugs Exp Clin Res ; 16(7): 361-9, 1990.

Article in En | MEDLINE | ID: mdl-2152694

Subject(s)

Adenocarcinoma/drug therapy; Peptides/therapeutic use; Prostatic Neoplasms/drug therapy; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols/administration & dosage; Antineoplastic Combined Chemotherapy Protocols/therapeutic use; Diethylstilbestrol/administration & dosage; Diethylstilbestrol/therapeutic use; Drug Administration Schedule; Drug Combinations; Humans; Male; Middle Aged

Search on Google

Add to My VHL

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Peptides / Prostatic Neoplasms / Adenocarcinoma Limits: Aged / Aged80 / Humans / Male / Middle aged Language: En Journal: Drugs Exp Clin Res Year: 1990 Document type: Article Country of publication: Switzerland

Search on Google

Add to My VHL

XML

PubMed Links